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Background: In physiologic and pathologic conditions of the central nervous system (CNS), astrocytes are a
double-edged sword. They not only support neuronal homeostasis but also contribute to increases in neuronal
demise. A large body of experimental evidence has shown that impaired astrocytes play crucial roles in the
pathologic process of cerebral ischemia; therefore, astrocytes may represent a breakthrough target for
neuroprotective therapeutic strategies. Agmatine, an endogenous polyamine catalyzed from L-arginine by
arginine decarboxylase (ADC), is a neuromodulator and it protects neurons/glia against various injuries.
Results: In this investigation, agmatine-producing mouse cortical astrocytes were developed through transduction
of the human ADC gene. Cells were exposed to oxygen-glucose deprivation (OGD) and restored to a normoxic
glucose-supplied condition. Intracellular levels of agmatine were measured by high performance liquid chromatography.
Cell viability was evaluated by Hoechest/propidium iodide nuclear staining and lactate dehydrogenase assay. Expression
of inducible nitric oxide synthase (iNOS) and matrix metalloproteinase s (MMPs) were assessed by a reverse transcription
polymerase chain reaction, Western immunoblots, and immunofluorescence. We confirmed that ADC gene-expressed
astrocytes produce a great amount of agmatine. These cells were highly resistant to not only OGD but also restoration,
which mimicked ischemia-reperfusion injury in vivo. The neuroprotective effects of ADC seemed to be related to its
ability to attenuate expression of iNOS and MMPs.
Conclusion: Our findings imply that astrocytes can be reinforced against oxidative stress by endogenous agmatine
production through ADC gene transduction. The results of this study provide new insights that may lead to novel
therapeutic approaches to reduce cerebral ischemic injuries.
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Astrocytes comprise the structural architecture of the
brain and support neurons to maintain homeostasis [1,2].
Physiologically, they stabilize the extracellular environment
of neurons: they control ion/water distribution, regulate
neurotransmitter recycling, release growth factors, and
scavenge reactive oxygen species (ROS). Under patho-
logic conditions, when noxious stress exceeds limitations,
astrocytes work in the opposite direction [1,2]. Water accu-
mulation induces brain edema, failure of neurotransmitter* Correspondence: jelee@yuhs.ac
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unless otherwise stated.control, which causes glutamate excitotoxicity; and releases
ROS/neurotoxic factors that contribute to further neuronal
damage. In cerebral injuries, astrocytes are the main culprit
of neurodegeneration and scar formation [2,3]. Meanwhile,
they also contribute to neurite outgrowth and neurogenesis
[4]. Astrocytes have recently garnered attention as a break-
through target in development of new therapeutic strategies
for patients suffering from neuronal damage [2].
Agmatine, an endogenous polyamine derived from
L-arginine by arginine decarboxylase (ADC), is naturally
found in the mammalian central nervous system (CNS)
and acts as a multifunctional neuromodulator [5-7]. It is
packed into synaptic vesicles and released from synapto-
somes by neuronal depolarization [8,9]. Agmatine can
stimulate α2-adrenergic and imidazoline receptors [10,11],td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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and voltage-gated calcium channel [12,13], and inhibit
inducible/neuronal nitric oxide synthases (iNOS/nNOS)
[14,15]. Through these kinds of intracellular signaling,
agmatine shows various antineurotoxic, anticonvulsant,
antipsychotic, antidepressant, anxiolytic, and antinocicep-
tive neuroprotective effects [7,16]. Regarding ischemic
insults, exogenous agmatine significantly reduces the
infarct size and brain edema caused by ischemia-
reperfusion injury in rodents [17-20]. Agmatine also
rescues glial cells, as well as cortical neurons, from
oxidative stress in vitro and in vivo [17,21,22].
In this study, a recombinant retroviral vector containing
the human ADC (hADC) gene was introduced into mouse
cortical astrocytes to maximize the astrocyte-protective
effect of agmatine. Cells overexpressing hADC show
increased production of agmatine and greater resistance
against oxidative stress [23-25]. Here, we transduced
primary cultured cortical astrocytes with hADC-expressing
retroviral vector and assessed whether it induces synthesis
of endogenous agmatine and attenuates oxidative stress
injuries.Methods
Cell culture
Primary cortical astrocyte cultures were prepared from
postnatal 1–3 days old Crl:CD1 mouse pups (Samtako,
Osan, Korea) [21,26]. Our protocol was approved by the
Institutional Animal Care and Use Committee of Yonsei
University College of Medicine and all animals were
treated in accordance with their guidelines. Animals were
etherized and decapitated on ice-cold ethanol. Cortical
hemispheres were dissected free of the skull and meninges,
and then treated with 0.09% trypsin for 20 min at 37°C.
The cells were mechanically dissociated into single cells
and collected as a suspension. The cells were grown in
minimum essential medium (MEM; Life Technologies,
Grand Island, NY) containing 10% fetal bovine serum
(FBS) and 10% equine serum (Thermo Fisher Scientific,
Waltham, MA). The cultures were incubated at 37°C in a
5% CO2 incubator and the culture media was replaced
every 3 days. One week after the first seeding, the other
cells including microglia were removed by vigorous
shaking. The highly-purified astrocytes (passage 3), at least
3 weeks after the first seeding, were used for experiments
at about 80% confluence (Additional file 1).Construction and infection of recombinant retroviral
vector containing the hADC gene
A recombinant retroviral vector containing the hADC
gene was constructed as described previously (Figure 1)
[23-25]. Briefly, the full-length cDNA of hADC (GenBank
accession no. AY325129) was amplified by a polymerasechain reaction (PCR) and ligated to the retroviral expres-
sion vector pLXSN (Clontech Laboratories, Mountain
View, CA) that also contained a neomycin resistance gene.
They were then amplified in E.coli DH5a and identified by
restriction analysis. The hADC-expressing pLXSN vector
was transfected into the retroviral packaging cell line
PT67 using Lipofectamine 2000 (Sigma-Aldrich, St. Louis,
MO). A stable clone selection was carried out by adding
G418 (200 μg/mL; Sigma-Aldrich) to the culture medium
of Dulbecco’s modified Eagle’s medium (DMEM, Life
Technologies) supplemented with 10% FBS. High-titer
clones were selected, and virus-containing supernatant
was filtered through a 0.45-mm polysulfonic filter. Pri-
mary cultured mouse cortical astrocytes were infected
with hADC pLXSN. The cells were incubated with the
virus-containing media for 24 hrs and then maintained in
normal culture medium for a week before being used for
the experiments.Oxygen-glucose deprivation and restoration
For oxygen-glucose deprivation (OGD), cultures were
transferred to a closed anaerobic chamber (Forma Sci-
entific Co., Seoul, Korea) in which the oxygen level (less
than 0.1% O2) and temperature (37°C) were controlled
automatically [21,27]. After being washed three times
with deoxygenated, glucose-free balanced salt solution
(BSS0) at pH 7.4, cells were kept in the anaerobic chamber
for 4 hours. Cultures were then restored with glucose
at a concentration of 5.5 mM (BSS5.5) and recovered to
normoxic conditions (37°C, 5% CO2) for up to 10 hours.High performance liquid chromatography analysis
The concentration of agmatine was measured by high
performance liquid chromatography (HPLC) [23,24]. Har-
vested cells were homogenized in phosphate buffer
containing 10% trichloroacetic acid and centrifuged at
12,000 rpm for 10 min. The collected supernatant was
derivatized with o-phthalaldehyde and loaded onto the
HPLC column (5 mm) connected with a fluorescence
detector. Recovery of agmatine was calculated from an
added external standard. The content of L-Arginine
and putrescine was also measured using same method.Hoechst and propidium iodide nuclear staining
Cell death was characterized by double nuclear staining
with Hoechst 33258 and propidium iodide (PI) [23,24].
Cells were stained with Hoechst 33258 dye (5 μg/mL;
Sigma-Aldrich) for 30 min at 37°C and consecutively
stained with PI (5 μg/mL; Sigma-Aldrich) just before
observing it with a fluorescence microscope. Living
cells showed Hoechst-positive blue fluorescence and
nonviable cells had PI-positive red fluorescence.
Figure 1 Construction and infection of recombinant retroviral vector containing the human arginine decarboxylase (hADC) gene.
(A) hADC pLXSN vector map: hADC pLXSN includes the Col E1 origin of replication and E.coli Ampr gene for propagation and antibiotic selection.
The 5' viral LTR in this vector contains promoter/enhancer sequences that control expression of the gene of interest in the multiple cloning site.
The SV40 early promoter (PSV40e) controls expression of the neomycin resistance gene (Neo
r), which allows antibiotic selection in eukaryotic cells.
(B) Genetic confirmation by restriction analysis: Lane 1, size marker; Lane 2, restriction enzyme digestion using EcoRI and XhoI; Lane 3, control
hADC pLXSN. (C) RNA levels of hADC were verified by RT-PCR in PT67 cells and mouse cortical astrocytes (Astro) after hADC pLXSN infection.
(D) Expression of hADC was validated by immunocytochemistry in hADC pLXSN-infected astrocytes. Scale bar = 50 μm.
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Cell viability was quantified by measuring the amounts of
lactate dehydrogenase (LDH) released from injured cells
into the medium [27-30]. LDH released (% cytotoxicity)
was calculated by dividing the value at the experimental
time point by the maximum value × 100. Maximum LDH
release values were obtained after freezing each culture
at −70°C overnight and then rapidly thawing them, thus
inducing nearly complete cell damage.
Reverse transcription polymerase chain reaction
Gene expression was assessed by reverse transcription
PCR (RT-PCR) [23,24]. Total RNA was extracted from
cells with Trizol (Life Technologies) and quantified by
measuring the absorbance at 260 nm. cDNA synthesis
from mRNA and normalization of the samples were
carried out by RT-PCR. PCR amplification of iNOS was
performed at 94°C for 30 s, 57.5°C for 30 s, and 72°C for
30 s for 30 cycles. Amplification of MMP-2 was performed
at 94°C for 30 s, 53°C for 30 s, and 72°C for 30 s for
35 cycles. Amplification for MMP-9 was performed at
94°C for 30 s, 59°C for 30 s, and 72°C for 30 s for 30 cycles.
Specific primer sequences used are as follows: iNOS, sense5'-TTT GAT GTG CTG CCT CTG GT-3' and antisense
5'-CAT TCT GCT TCT GGA AAC TAA GG-3'; MMP-2,
sense 5'-GAG TTG GCA GTG CAA TAC CT-3' and
antisense, 5'-GCC GTC CTT CTC AAA GTT GT-3';
MMP-9, sense 5'-TTA CCA GCG CCA GCC GAC
TTT TG-3' and antisense 5'-CGT CGT CGT CGA
AAT GGG CAT C-3'; Glyceraldehyde 3-phosphate de-
hydrogenase (GAPDH), sense 5'-ATG TCG TGG AGT
CTA CTG GT-3' and antisense 5'-TGG CAT GGA CTG
TGG TG-3'. PCR products were separated by electrophor-
esis in a 1.5% agarose gel stained with ethidium bromide.
Western immunoblots
Protein levels were determined by Western immunoblots
[23,24,31]. Protein was extracted from whole cell lysates,
and their concentration was calculated with the BCA
protein assay (Thermo Fisher Scientific). Equal amounts
of protein (40 μg) from each sample were resolved on a
10% sodium dodecyl sulfate-polyacrylamide gel. The
separated proteins were then electrotransferred onto
Immobilon-NC membranes (Millipore, Billerica, MA)
and incubated overnight with primary antibodies against
iNOS (1:1000 dilution), MMP-2 (1:2000 dilution), MMP-9
Figure 2 Endogenous agmatine measurement using high
performance liquid chromatography (HPLC). The level of amines
related to the agmatine pathway was determined in mouse cortical
astrocytes infected with retrovirus containing the human arginine
decarboxylase (hADC) gene. Cells underwent oxygen-glucose deprivation
(OGD) for 4 hrs. Data are expressed as a mean ± SD of three different
experiments performed from separate cell preparation, with triplicate
determinations performed in each experiment. Asterisks indicate a
p < 0.001 when the samples were compared to no treatment control.
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antibody against iNOS was purchased from Millipore
(Billerica, MA) and the others were obtained from Santa
Cruz Biotechnology (Dallas, TX). Immunoreactive bands
were detected with horseradish peroxidase-conjugated
secondary antibody and visualized using an enhanced
chemiluminescent protein detection kit (Thermo Fisher
Scientific).
Immunofluorescence staining
Protein expression was also confirmed by immunofluor-
escence [23,31,32]. Cells were fixed with 90% ethanol
for 30 min on ice, and then treated with 1.6% hydrogen
peroxide and 0.025% triton. They were reacted with
specific antibodies (1:500 dilution) for iNOS (Millipore),
MMP-2 (Santa Cruz Biotechnology), MMP-9 (Santa Cruz
Biotechnology), and glial fibrillary acidic protein (GFAP;
Abcam, Cambridge, MA). Subsequently, the cells were
exposed to the corresponding fluorescent secondary
antibodies (Life Technologies) and their nuclei were
counterstained with 4’,6-diamidino-2-phenylindole (DAPI;
Sigma-Aldrich). Finally, four random fields were imaged
under a fluorescence microscope. Immunoreactive cells with
fluorescence were manually counted at 200× magnification.
Statistical analysis
Data are presented at the mean of ± SD of at least three
different experiments performed from separate cell prepa-
rations, with at least triplicate determination performed for
each experiment. Kruskal-Wallis test and Mann–Whitney
test were used in order to examine statistical significance
(MedCalc Statistical Software version 12.7.8.; MedCalc Soft-
ware bvba, Ostend, Belgium). P-values less than 0.05 were
considered statistically significant.
Results
Transduction of mouse cortical astrocytes with
recombinant retroviral vector containing the human
arginine decarboxylase (hADC) gene
The vector map of hADC pLXSN is shown in Figure 1A.
It includes the Col E1 origin of replication and E.coli
Ampr gene for propagation and antibiotic selection. The
5' viral LTR contains promoter/enhancer sequences that
control expression of the gene of interest in the multiple
cloning site. The SV40 early promoter (PSV40e) controls
expression of the neomycin resistance gene (Neor),
which allows for antibiotic selection in eukaryotic cells.
PSV40e was genetically confirmed by restriction analysis
(Figure 1B). In astrocytes, as well as PT67 cells, infection
of the hADC pLXSN vector effectively induced hADC
transcription (Figure 1C). Expression of hADC was vali-
dated by immunocytochemistry in hADC pLXSN-infected
astrocytes (Figure 1D).Endogenous agmatine production from human arginine
decarboxylase (hADC)-overexpressed astrocytes
Intracellular levels of agmatine were measured by HPLC
(Figure 2). Endogenous agmatine concentration was mark-
edly greater for astrocytes overexpressing hADC compared
to that of control astrocytes (11.28-fold, p < 0.001). The
amount of L-arginine and putrescine (precursor and
metabolite of agmatine, respectively) showed similar ten-
dency to that of agmatine. Meanwhile, OGD itself did not
have a significant influence on the level of these amines.
Astrocyte-protective effect of human arginine decarboxylase
(hADC) transduction against oxygen-glucose deprivation
(OGD)
OGD damaged naive astrocytes and the majority of cells
had PI-labeled nuclei (Figure 3B). However, astrocytes
overexpressing hADC (hADC-astrocytes) were much
less damaged by OGD, and the proportion of PI-positive
cells were considerably lower (Figure 3D). hADC trans-
duction itself did not have any significant effects on cell
viability (Figure 3C), as determined by Hoechst 33258
and PI double nuclear staining.
Neuroprotective effect of human arginine decarboxylase
(hADC) transduction on oxygen-glucose deprivation
(OGD) and restoration injury
To mimic the ischemia-reperfusion injury in vivo, cells
were restored to normoxic glucose-supplied conditions
after 4 hrs of OGD (Figure 4). Cytotoxicity was measured
by LDH leakage from the injured cells. Cytotoxicity grad-
ually increased in a time-dependent manner for up to
10 hrs during restoration. Even in hADC-astrocytes, the
Figure 3 Astrocyte-protective effect of human arginine decarboxylase (hADC) transduction against oxygen-glucose deprivation (OGD).
Cytotoxicity was assessed by Hoechst 33258 and propidium iodide (PI) nuclear staining; (A) No treatment control astrocytes, (B) astrocytes after
4 hrs OGD, (C) hADC-overexpressing astrocytes (hADC-astrocytes), (D) hADC-astrocytes after 4 hrs OGD. Scale bars = 100 μm. (E) Proportion of
PI-labeled damaged cells with red fluorescence. Asterisks indicate a p < 0.05 when the samples were compared to no treatment control. Double
asterisk indicate a p < 0.05 that that the two samples were significantly different which was confirmed by a post-hoc analysis.
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dependent-manner; the extent of damage was much less
than that in control astrocytes.Suppression of inducible nitric oxide synthase (iNOS) and
matrix metalloproteinases (MMPs) in human arginine
decarboxylase (hADC)-overexpressing astrocytes
Expression of iNOS and MMP-2/9 was assessed by RT-
PCR (Figure 5A) and Western immunoblots (Figure 5B).
OGD significantly increased levels of iNOS and MMP-2/9;
however, hADC transduction attenuated the OGD effects.
Introduction of the hADC gene itself did not changeglyceraldehyde 3-phosphate dehydrogenase (GAPDH)
and β-actin levels, which served as internal controls for
RT-PCR and Western immunoblots, respectively.Inhibited expression of inducible nitric oxide synthase
(iNOS) and matrix metalloproteinases (MMPs) in human
arginine decarboxylase (hADC)-transduced astrocytes
Naive astrocytes seldom expressed iNOS and MMP-2/9
(Figure 6A,D,G). After 4 hrs of OGD, control astrocytes
exhibited expression of iNOS and MMP-2/9 (Figure 6B,
E, H); however, hADC-astrocytes did not show immuno-
reactivity to either iNOS or MMP-2/9 (Figure 6C, F, I).
Figure 4 Neuroprotective effect of human arginine decarboxylase
(hADC) transduction against oxygen-glucose deprivation
(OGD) and restoration injury. Astrocytes restored to normoxic
glucose-supplied conditions after 4 hrs OGD. Cytotoxicity was assessed
by the lactate dehydrogenase (LDH) assay. Data are expressed as mean
of ± SD of the three different experiments performed from separate
cell preparations, with triplicate determinations performed in each
experiment. Asterisks indicate a p < 0.001.
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Since Reis and colleagues first discovered agmatine and
ADC activity in the mammalian brain [5], agmatine has
been widely studied. It is known to have various biological
actions through multiple molecular targets, exhibitingFigure 5 Inducible nitric oxide synthase (iNOS) and matrix metalloprote
(hADC)-introduced astrocytes after oxygen-glucose deprivation (OGD).
polymerase chain reaction (RT-PCR) (A) and protein expression was evaluated
dehydrogenase (GAPDH) and β-actin were used as internal controls, respectiv
no treatment control. Double asterisk indicate a p < 0.05 that two samples weaffinity not only to α2-adrenoceptors and I1- and I2-imida-
zoline receptors but also to β-adrenoceptors and 5-HT3
serotonin, nicotinic cholinergic NMDA, D2-dopamine, κ-
opioid, and adenosine A1 receptors [10-12]. Agmatine also
inhibits iNOS/nNOS and monoamine oxidase [10,14,15].
As well, agmatine reduces heart rate and blood pressure
[10], stimulates insulin and β-endorphin release, leading
to increased cellular glucose uptake [33,34], and accel-
erates glomerular ultrafiltration [35]. Agmatine protects
systemic organs, especially against oxidative stress. Add-
itionally, it shows cardioprotective and renoprotective
effects on ischemic insult [36,37], and it directly protects
mitochondria from ROS [38,39]. In the CNS, agmatine
shows neuroprotective effects on various neuronal injuries:
reduces the infarct size and edema after cerebral ischemia
[17,18,40], attenuates brain damage and reactive gliosis
caused by trauma [41,42], and also decreases traumatic/
ischemic spinal cord injuries [43,44]. Agmatine also
decreases neuropathic pain and convulsive events [45,46],
attenuates opioid dependence and alcohol withdrawal
anxiety [47,48], and it improves motor and cognitive
functions in Parkinson's and Alzheimer's disease, respect-
ively [49,50]. Even in the eyes, agmatine lowers intraocularinases (MMPs) expression in human arginine decarboxylase
The mRNA levels were determined using reverse transcription
using Western immunoblots (B). Glyceraldehyde 3-phosphate
ely. Asterisks indicate a p < 0.05 when the samples were compared to
re significantly different which was confirmed by a post-hoc analysis.
Figure 6 Immunofluorescence staining of human arginine decarboxylase (hADC)-introduced astrocytes after oxygen-glucose
deprivation (OGD). (A, D, G) No treatment control astrocytes; (B, E, H) astrocytes after 4 hrs OGD; (C, F, I) hADC-astrocytes after 4 hrs OGD. Cells
reacted to inducible nitric oxide synthase (iNOS) (A-C), matrix metalloproteinase (MMP) 2 (D-F), and MMP 9 (G-I) showed green fluorescence. Cells
were counter-stained with astrocyte marker glial fibrillary acidic protein (GFAP; red fluorescence) and nuclear marker 4',6-diamidino-2-phenylindole
(DAPI; blue fluorescence). Scale bar = 50 μm.
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together, agmatine seems to be a miracle cure rather than
a specific drug.
In routine clinical settings, exogenous drug adminis-
tration may be the most straightforward therapeutic
strategy. However, exogenous drug administration is not
always the best approach for real patients. Taken orally,
agmatine is readily distributed throughout the body
[53,54] and can even cross the blood–brain barrier [55,56].
Moreover, its reported half-life in the body is about 2 hrs
[57]. The various functions of agmatine have pros and
cons. In addition to neuronal effects, agmatine also has
cardiovascular, endocrinal, renal, gastric, and growth
effects [10]. Therefore, taken orally, agmatine may cause
unwanted systemic responses. Thus, it is important to
focus on the action of the drug at the site of injury and
extend its duration of action. In this regard, in the oph-
thalmologic field, a topical agmatine ophthalmic solution
has been formulated to preserve the optic nerves against
glaucomatous damage [51]. Agmatine eye drops effectively
lower intraocular pressure and protect retinal ganglion
cells from chronic ocular pressure injuries. Along the
same lines, investigators have attempted to develop a
distinctive method for increasing endogenous agmatine
production via a recombinant retroviral vector system
containing the hADC gene. The hADC gene can beeffectively delivered into mouse fibroblast NIH3T3 cells
[23], primary mouse cortical neural stem cells [24], and
human bone marrow mesenchymal stem cells [25]. Dif-
ferent types of transformed cells synthesize agmatine
when they are exposed to hydrogen peroxide, resulting
in resistance against oxidative stress. Irrespective of the
cell type in an oxidative stressed environment, intracellular
agmatine concentration is boosted by about 2 to 5-fold in
hADC-overexpressing cells compared to no treatment
control cells, as determined by HPLC [23-25]. While in
normal culture conditions, agmatine synthesis is signifi-
cantly increased in cortical neural stem cells [24] but
not fibroblasts or mesenchymal stem cells [23,25]. It is
not yet clear why the activity of an introduced hADC gene
differs according to cell type, especially in non-stressful
conditions; nonetheless, it is assumed that agmatine
controls the expression of the introduced hADC gene.
If normal cells use little agmatine, the transformed cells
are presumed not to utilize the introduced ADC with-
out harmful stimuli. However, if normal cells actively
use agmatine, the transformed cells are presumed to
utilize the introduced ADC. When cells are attacked,
all the cell types seem to use the introduced ADC.
In this investigation, we focused on cortical astrocytes,
which have recently came to the forefront due to their
suspected roles in many CNS injuries, including cerebral
Hong et al. BMC Neuroscience 2014, 15:99 Page 8 of 10
http://www.biomedcentral.com/1471-2202/15/99ischemia [2,3]. Our results showed that intracellular
levels of agmatine, as well as its precursor arginine and
byproduct putrescine, are definitively increased (about
11-fold compared to the control, p < 0.001) in normal
and oxidative stressed conditions upon hADC gene
transduction, as measured by HPLC. Simultaneously, cell
viability was determined by Hoechst /PI double nuclear
staining and the LDH assay. hADC-overexpressing cells
remained viable and healthy under oxidative stress condi-
tions induced by OGD for 4 hrs. This astrocyte-rescuing
property was gradually potentiated as restoration time
proceeded for up to 10 hours. In addition, the neuro-
protective effect of endogenous agmatine seemed to be
related to iNOS intracellular signaling and the activity
of MMPs, as assessed by RT-PCR, Western immunoblots,
and immunofluorescence. Our present and previous find-
ings are similar to those of other groups in regards to
iNOS [15,58-60] and MMPs [61,62], respectively. As
MMPs are upregulated by ischemic insult and degrade
the basement membrane of brain microvessels [63],
their suppression via ADC gene transduction may reduce
ischemic injuries. Our retroviral system to deliver the
hADC gene to target cells cannot be directly applied to
non-dividing cells. Accordingly, another vector system
using the Lentivirus is currently under development. It
may be directly applied to non-dividing CNS neurons,
specifically through in vivo transduction.Conclusion
In summary, our findings imply that endogenous agmatine
production through ADC gene transduction can protect
astrocytes against oxidative stress. The results of this study
provide new insights that may lead to novel therapeutic
approaches to reduce oxidative stress-related diseases
including cerebral ischemia.Additional file
Additional file 1: Immunofluorescence staining of primary cultured
astrocytes. Cells reacted to anti-glial fibrillary acidic protein (GFAP) (A, red
fluorescence), and anti-CD11b (B, green fluorescence) antibodies. Nuclei
were counterstained with Hoechst 33258 (C, blue fluorescence). Panel D is
a merged image. Scale bar = 200 μm.Abbreviations
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